Affordability of Insulin for Non-Elderly Adults in the United States following $35 Monthly Out-of-Pocket Cap

Excerpt

Prior studies have shown that nearly one in seven Americans using insulin experience catastrophic healthcare spending due to the out-of-pocket (OOP) spending on insulin. ¹ The 2022 Inflation Reduction Act capped OOP spending to $35 per insulin product for Medicare patients, but no provisions were made for non-Medicare patients, who pay an estimated $474 per year on insulin. ^{2, 3} In March 2023, the three major insulin manufacturers announced price reductions, with both Elil Lilly and Sanofi adding a $35 OOP cap to their insulin products. ⁴ Which non-Medicare populations are most likely to benefit and how much will be saved with a $35 insulin OOP cap remain unclear. …